Clinical-stage biopharmaceutical company BIND Biosciences has reported promising preclinical data from the Phase 1 clinical study of BIND-014 in patients with advanced or metastatic cancers.
BIND-014 is a programmable nanomedicine that combines a targeting ligand and a therapeutic nanoparticle to act against prostate specific membrane antigen (PSMA), a cell surface antigen expressed on the surface of cancer cells and on new blood vessels that feed a wide array of solid tumours.
Go deeper with GlobalData
The open label pharmacokinetic and pharmacodynamic dose escalation Phase 1 study was intended to evaluate the safety, tolerability and maximum tolerated dose of BIND-014 and to determine preliminary evidence of antitumour activity.
The preliminary Phase 1 data suggested that BIND-014 demonstrated partial response or stable disease in the pretreated patient population with durable responses of up to six months in some cases.
In addition, BIND-014 showed evidence of antitumour activity in tumours for which conventional docetaxel is known to have minimal activity.
See Also:
At all dose levels studied, with 75mg/m² reached to date, BIND-014 was generally well-tolerated with no new toxicities observed, the company said.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataBIND Biosciences president and chief executive officer Scott Minick said the encouraging Phase 1 data will support the company to advance BIND-014 into Phase 2 development planned later this year.
"In addition, these data show the emerging potential of BIND-014 to be a significant new cancer therapy for patients by fundamentally changing the pharmacology of docetaxel, allowing it to differentially concentrate in the tumours by up to ten-fold, as shown in our preclinical models, for better clinical efficacy across multiple cancers, including those in which conventional docetaxel has minimal activity," Minick added.
"BIND-014 is the clinical validation of BIND’s Accurin technology platform, and marks an important milestone for the field of nanomedicine, BIND and, most importantly, patients."
In preclinical cancer models, BIND-014 was found to deliver up to ten-fold more docetaxel to tumours than an equivalent dose of conventional docetaxel, thereby improving antitumour activity and tolerability.
The development of BIND-014 was funded in part by the National Cancer Institute and the US National Institutes of Standards and Technology (NIST) under its Advanced Technology Programme (ATP).
